Retrospective Analysis of a Cohort of Patients with Metastatic Bladder Cancer with Metastatic Sites Limited to the Pelvis and Retroperitoneum Treated at a Single Institution between 2009 and 2020.
bladder cancer
multidisciplinary approaches
oligometatasis disease
radiochemotherapy
radiotherapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Mar 2023
30 Mar 2023
Historique:
received:
21
02
2023
revised:
25
03
2023
accepted:
29
03
2023
medline:
14
4
2023
entrez:
13
4
2023
pubmed:
14
4
2023
Statut:
epublish
Résumé
Bladder cancer (BC) presenting with pelvic and retroperitoneal lymph nodes presents a therapeutic challenge. The impact of chemoradiotherapy on pelvic and retroperitoneal lymph node metastasis as a consolidation treatment has not been established. Between 2009 and 2020, 502 patients who were treated with first-line chemotherapy for BC in our center, were retrospectively identified. Patients who received chemoradiotherapy or radiotherapy with an equivalent radiation dose superior to 30 Gy were included in the RTCT group, and other patients were included in the control group (CT group). We performed an analysis of progression-free survival (PFS) and overall survival (OS) for these two cohorts using the Kaplan-Meier method. A total of 89 patients were included, 24 in the RTCT group and 65 in the CT group. Chemoradiotherapy improved both OS (
Identifiants
pubmed: 37046728
pii: cancers15072069
doi: 10.3390/cancers15072069
pmc: PMC10093406
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Semin Thorac Cardiovasc Surg. 2008 Fall;20(3):204-9
pubmed: 19038729
Clin Genitourin Cancer. 2017 Dec;15(6):685-688
pubmed: 28465049
Eur J Cancer. 2022 May;166:254-269
pubmed: 35339868
Acta Oncol. 2013 Nov;52(8):1622-8
pubmed: 23544357
Front Oncol. 2013 Jan 22;2:215
pubmed: 23346551
N Engl J Med. 2020 Sep 24;383(13):1218-1230
pubmed: 32945632
Eur Urol. 2019 Oct;76(4):425-429
pubmed: 31303258
Lancet. 2018 Dec 1;392(10162):2353-2366
pubmed: 30355464
Oncotarget. 2015 Apr 20;6(11):8491-524
pubmed: 25940699
J Clin Oncol. 2017 Jul 10;35(20):2299-2305
pubmed: 28410011
Jpn J Clin Oncol. 2020 Feb 17;50(2):206-213
pubmed: 31665467
Lancet Oncol. 2017 May;18(5):672-681a
pubmed: 28389316
Eur Urol. 2017 Jan;71(1):96-108
pubmed: 27370177
Ann Oncol. 2014 Sep;25 Suppl 3:iii40-8
pubmed: 25096609
Lancet Oncol. 2017 Nov;18(11):1483-1492
pubmed: 28967485
J Clin Oncol. 2020 Jun 1;38(16):1797-1806
pubmed: 32271672
Clin Oncol (R Coll Radiol). 2021 Jan;33(1):50-56
pubmed: 32723486
JAMA Oncol. 2017 Sep 14;3(9):e172411
pubmed: 28817753
J Clin Oncol. 2000 Sep;18(17):3068-77
pubmed: 11001674
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
Lancet. 2020 May 16;395(10236):1547-1557
pubmed: 32416780
J Clin Oncol. 2016 Oct 10;34(29):3529-3536
pubmed: 27269944
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Clin Oncol. 2017 Jan;35(1):48-55
pubmed: 28034079
J Clin Oncol. 2012 Apr 1;30(10):1107-13
pubmed: 22370319
Cancer. 2014 Mar 1;120(5):692-701
pubmed: 24249435
J Clin Oncol. 2019 Jun 20;37(18):1558-1565
pubmed: 31067138
Clin Colorectal Cancer. 2022 Jun;21(2):e78-e86
pubmed: 34903471
Lancet Oncol. 2020 Jan;21(1):e18-e28
pubmed: 31908301